Sustained High Prevalence of Multiple Antimalarial Drug Resistance Markers in Uganda in 2023-24

This study reveals that in 2023–24, Uganda experienced sustained high prevalence and geographic heterogeneity of multiple antimalarial drug resistance markers, including specific *K13* mutations associated with artemisinin partial resistance and widespread antifolate resistance, underscoring the urgent need for continued nationwide molecular surveillance to guide treatment policies.

The Gist

Imagine Uganda as a vast, bustling city where a tiny, invisible enemy called Plasmodium falciparum (the malaria parasite) is constantly trying to break in and cause chaos. For years, the city's security team (doctors and scientists) has had a specific set of keys (medicines) to lock the doors and keep the enemy out.

This new report is like a security audit conducted in 2023 and 2024. The scientists went to 32 different neighborhoods (health centers) across the country to check if the enemy has learned how to pick the locks.

Here is the breakdown of what they found, using simple analogies:

1. The Master Lockpickers (Artemisinin Resistance)

The most important key the security team uses is a fast-acting medicine called Artemisinin. It's the "Master Key" that starts the process of killing the parasite.

• The Problem: The parasites have started making "lockpicks" (genetic mutations called K13 mutations) that allow them to survive the initial attack.
• The Map of Trouble: The lockpicks aren't the same everywhere. It's like different gangs in different neighborhoods using different tools:
  • Northern Uganda: The gangs here mostly use two specific picks (A675V and C469Y).
  • Western Uganda: They prefer a different tool (P441L).
  • Southwestern Uganda: They are using a unique, rare set of picks (R561H and C469F).
• The Good News: For a while, everyone thought these lockpicks would take over the whole city. But the audit shows that in many places, the number of lockpickers has stopped growing. They hit a "ceiling." It seems the parasites are stuck in a tug-of-war: being resistant helps them survive the medicine, but it also makes them slightly weaker in other ways, so they can't completely take over.

2. The Old Keys Making a Comeback (Chloroquine Resistance)

Years ago, the city stopped using an old key called Chloroquine because the parasites learned to ignore it. The parasites threw away their "ignore" buttons.

• The Surprise: In the Northwest (near the borders with South Sudan and the DRC), the parasites have dug up those old "ignore" buttons and started using them again.
• Why? It's likely because their neighbors across the border are still using the old medicine (Amodiaquine), and the parasites are sneaking back across the border with those old tricks. They are also finding a new trick (H97L) that works even better with the old ones.

3. The Broken Backup Plan (Sulfadoxine-Pyrimethamine Resistance)

When the main keys fail, the city has a backup plan for pregnant women and children: a drug called SP. It's like a secondary security system.

• The Crisis: The parasites have completely mastered this system. They have a "Super-Hack" (a combination of five mutations) that is now everywhere.
• The Upgrade: Even worse, in the Southwest, the parasites have added two more hacks to their toolkit. This means the backup plan is practically useless in those areas. It's like trying to lock a door with a piece of tape when the lock is already broken.

4. The Big Picture: A Patchwork Quilt

If you look at the whole country, it's not a uniform disaster; it's a patchwork quilt.

• Some areas are fighting a specific type of resistance.
• Others are fighting a different type.
• Some are seeing old problems return.

What Does This Mean for the Future?

The security team (public health officials) is getting a clear message: The old keys are wearing out, and the enemy is getting smarter.

• We can't rely on the same medicine everywhere. A medicine that works in the North might fail in the South.
• We need new keys. The report suggests we might need to rotate different medicines (like changing the locks every few years) or use "triple locks" (three medicines at once) to stay ahead.
• We need to keep watching. Just because the lockpicking stopped growing in one place doesn't mean it won't start again tomorrow. Constant surveillance is the only way to catch the enemy before they break in.

In short: Malaria in Uganda is evolving. The parasites are adapting to our medicines in different ways depending on where you live. To win this war, we need to stop using a "one-size-fits-all" approach and start using a smarter, more flexible strategy.

Technical Summary

1. Problem Statement

Malaria control in Uganda is threatened by the emergence and spread of drug resistance in Plasmodium falciparum. While Artemisinin-based Combination Therapies (ACTs) replaced older regimens in 2006, new resistance markers are compromising treatment efficacy.

• Artemisinin Partial Resistance (ART-R): Driven by mutations in the Kelch13 (K13) propeller domain, ART-R causes delayed parasite clearance.
• Partner Drug Resistance: Resistance to partner drugs (e.g., lumefantrine, amodiaquine) and chemopreventive agents (Sulfadoxine-Pyrimethamine, SP) is mediated by mutations in genes such as CRT, MDR1, DHFR, and DHPS.
• Knowledge Gap: While previous studies (2016–2022) identified emerging resistance, there was a lack of recent, nationwide molecular surveillance data (2023–2024) to determine if resistance is stabilizing, spreading, or evolving into new haplotypes, particularly given recent therapeutic efficacy studies suggesting declining performance of the first-line drug, Artemether-Lumefantrine (AL).

2. Methodology

The study employed a large-scale, cross-sectional molecular surveillance approach across Uganda.

• Study Sites & Population: Samples were collected from 32 Malaria Reference Centers (MRCs) across Uganda, covering diverse transmission intensities (from hyperendemic north/east to low-transmission southwest).
• Sample Collection:
  • Timeframe: 2023–2024 (four collection rounds).
  • Subjects: Symptomatic patients (>6 months) with microscopically confirmed uncomplicated P. falciparum malaria.
  • Volume: 17,673 dried blood spot (DBS) samples collected; 8,518 passed quality control (85% success rate).
• Sequencing & Genotyping:
  • Technology: Illumina MiSeq and NextSeq platforms.
  • Panel: MAD4HatTeR (Multiplex Amplicons for Drug, Diagnostic, Diversity, and Differentiation Haplotypes using Targeted Resequencing). This panel targets 118 key drug resistance markers and 165 microhaplotypes for diversity assessment.
  • Quality Control: Strict filtering for coverage (≥50 reads), allele support (≥10 reads), and within-sample allele frequency (WSAF ≥0.75%). Sample duplication was identified via Jaccard index and WSAF analysis; highly duplicated sites were excluded.
• Data Analysis:
  • Prevalence Calculation: Single-locus and multilocus (haplotype) prevalence were estimated.
  • Historical Context: 2023–2024 data were integrated with previously published data (2016–2022) to analyze longitudinal trends.
  • Copy Number Variation (CNV): Analyzed for mdr1 and plasmepsin 2/3 (pm2/3) genes.

3. Key Contributions

• Nationwide Scope: Provides the most comprehensive recent dataset on antimalarial resistance in Uganda, covering 32 sites and over 8,500 sequenced samples.
• Longitudinal Insight: Combines current data with a 7-year historical dataset to distinguish between transient fluctuations and sustained trends in resistance.
• Novel Findings: Reports the first detection of the CRT H97L mutation in Africa and characterizes the geographic expansion of high-level antifolate resistance markers.
• Policy-Relevant Haplotypes: Moves beyond single SNPs to define complex, phased haplotypes (e.g., quintuple, septuple mutants) that better predict clinical resistance levels.

4. Key Results

A. Artemisinin Resistance (K13 Mutations)

• High Prevalence: Multiple validated/candidate K13 mutations (A675V, C469Y, P441L, R561H, C469F) were detected at ≥20% prevalence at various sites.
• Geographic Heterogeneity:
  • Northern Uganda: Dominated by A675V and C469Y.
  • Western Uganda: Dominated by P441L.
  • Southwestern Uganda: Confined to R561H and C469F (notably at Kamwezi MRC).
• Trend: After rapid increases in previous years, K13 mutation prevalences have plateaued at most sites.
  • Max site prevalences: C469Y (58%), P441L (46%), A675V (40%).
  • Implication: The rise may be limited by a fitness cost associated with these mutations, rather than unchecked spread.

B. Partner Drug Resistance (Aminoquinolines & Lumefantrine)

• Chloroquine (CQ) Re-emergence: The CRT K76T mutation (CQ resistance marker), previously declining, rose significantly in the West Nile region (Northwest), reaching 38–42% prevalence.
• Novel Mutation: The CRT H97L mutation (previously unreported in Africa) emerged in the same region, often co-occurring with K76T (99% linkage), suggesting a new resistant haplotype.
• MDR1: The N86Y mutation (associated with amodiaquine resistance) remained uncommon.
• Gene Amplification: mdr1 and pm2/3 copy number variations were extremely rare (<0.2% and <0.05%, respectively).

C. Antifolate Resistance (SP Resistance)

• Quintuple Mutant: The intermediate-resistance haplotype (DHFR N51I, C59R, S108N + DHPS A437G, K540E) is highly prevalent nationwide.
• High-Level Resistance:
  • DHFR I164L and DHPS A581G (conferring high-level SP resistance) are most common in Southwestern Uganda (up to 76% and 64% prevalence, respectively) but are expanding into Central and Eastern regions.
  • Septuple Haplotype: A complex haplotype containing all resistance markers (including I164L and A581G) reached 37% prevalence in the Southwest.

5. Significance and Implications

• Threat to First-Line Therapy: The sustained high prevalence of K13 mutations, combined with evidence of decreased lumefantrine susceptibility, suggests that Artemether-Lumefantrine (AL) is at risk of failure in Uganda.
• Chemoprevention Crisis: The widespread presence of high-level SP resistance markers (I164L, A581G) questions the efficacy of SP-based chemoprevention (IPTp and SMC). The study highlights that in regions with high resistance, SMC with SP-Amodiaquine (SPAQ) may offer little benefit over Amodiaquine alone while risking further selection of resistance.
• Geographic Specificity: The distinct geographic clustering of mutations (e.g., K13 types in the North vs. Southwest) implies that a "one-size-fits-all" national policy may be insufficient. Regionalized treatment strategies may be necessary.
• Urgent Policy Action: The authors call for:
  • Continued nationwide molecular surveillance.
  • Re-evaluation of SP-based chemoprevention strategies.
  • Consideration of alternative first-line regimens, rotating therapies, or triple-ACTs to mitigate resistance spread.
  • Characterization of the phenotype of the novel CRT H97L mutation.

Conclusion: The study confirms that Uganda is facing a complex landscape of multi-drug resistance. While K13 mutations have stabilized, the re-emergence of aminoquinoline resistance markers and the expansion of high-level antifolate resistance pose immediate threats to current malaria control and elimination efforts.